More on PFE
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $26.17 |
|
|||
| Open | $26.38 | ||||
| 52 Wk High | $37.39 | ||||
| 52 Wk Low | $28.25 | ||||
| Day High | $26.49 | ||||
| Day Low | $26.29 | ||||
| P/E | 16.03 | ||||
| EPS | $1.65 | ||||
| Volume | 2,527,282 | ||||
- Form 4 PFIZER INC For: Jun 09 Filed by: DAMICO JENNIFER B.
- Pfizer upgraded by RBC as valuation resets ahead of key pipeline catalysts
- RBC Capital Upgrades Pfizer (PFE) to Sector Perform
- Cancer's Toughest Targets Are Drawing Wall Street's Attention as Oncology Innovation Accelerates
- FDA approves expanded HYMPAVZI use for hemophilia patients with inhibitors
- U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
- Pfizer targets obesity market with monthly weight-loss injection data
- Pfizer reports phase 2b results for monthly obesity drug berobenatide
- Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide
- ADA 2026 preview: All eyes on these 2 stocks
Entities mentioned with PFE
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- Dividend | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Show More...
